About RenBio
RenBio is a private company based in Long Island City, New York, incorporated in 2020 in Delaware. It has reported $19,250,000 raised in two offerings on Form D since January 2021.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 22, 2024 | Sep 6, 2024 | $5,250,000of $6.0M target | 7 | $750K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 30, 2020 | Jan 19, 2021 | $14,000,000of $24.0M target | 7 | $2.0M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $19,250,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on RenBio's Form D filed Sep 6, 2024.
JD
Jaap Goudsmit, M.D., Ph.D.
Director
RD
Rachel Liberatore, Ph.D.
President and Chief Scientific Officer, director
ZD
Zhi Hong, Ph.D.
Director
DT
Donald Tang
Director
AR
Annelyn O'Rourke
Executive officer
WS
Walter Wang, Sr.
Director
Earlier filings also listed Wan Feng Ting (director, last listed Jan 2021), Tamon Tseng (director, last listed Jan 2021), Neal Padte (chief operating officer and director, last listed Jan 2021), David Chu (director, last listed Jan 2021) and Chi-Chuan Chen (director, last listed Jan 2021).